Preview 50% of the Answer Below
Answer Preview
This essay will discuss the mission statement of Motif Bio, a clinical-stage biopharmaceutical company that serves as a researcher and manufacturer of antibiotic drugs that combat multi-drug resistant bacteria, as well as the activities of the organization and the role that this organization plays in the U.S. healthcare system.
The mission of Motif Bio is to create novel antibiotics that are effective against infections caused by multi-drug resistant Gram-positive bacteria, such as MRSA. The company’s mission is especially timely, given the rapid increase in multi-drug resistant bacteria cases such as MRSA due to an increase in the misuse of antibiotics, and a growth in the complexity of the bacterial mutation environment. (Motif Bio, 2015)
The XXXXXXXXXXXX’s main activities are in research XXX XXXXXXXXXXX, XXXXXXXX trials, XXXXXXXXXX, XXXXXXXXXXXX, certification, branding XXX XXXXXX XXXXXXXXXXX. XXXXXXXX, the company XXXXXXX XXXXXXX in XXXXXXXX and development, especially through its lead product candidate of iclaprim, XXX XXXX XXXX XX XXXXX bacterial skin and XXXX XXXXXXXXX infections (XXXXXX), hospital XXXXXXXX XXXXXXXXX XXXXXXXXX (XXXX), XXX ventilor associated bacterial pneumonia (XXXX). (Motif XXX, 2019) XXX company then XXXXXXXX XXXXXXXX trials XX XXXXXX these XXXXXXXX are safe for administration to patients in situations XXXX as bacterial XXXXXXXXXX and XXXX surgeries. For example, XX XXXX, XXX company has XXXXXXXXX trials on nearly X,500 XXXXXXXX XXX healthy XXXXXXXXXX XX XXXXXX the overall effectiveness XXX side-XXXXXXX of XXXXXXXX, XXX XXXX drug XXXXXXXXX. These trials include XXXXXX-X, REVIVE-X and XXXXXXX trials, which are trials for ABSSSI, HABP and XXXX XXXXXXXXXXXX. The XXXXXXX also produces XXX distributes XXXXX XXXXX, and XX XXXXXXXXXXX XXX XXX safe, efficient XXX XXXX-effective production XXX XXXXXXXXXXXX XX XXXXX products to XXXXXXXXXXXX such XX clinics and XXXXXXXXX. The company also needs to certify XXX products XX XXXXXX XXXX XXXX XXX be XXXXXXXXXXX legally, XXXXXXX XXXXXXXXXXXXX XXXXXXXXX such as XXX Qualified XXXXXXXXXX XXXXXXX XXXXXXX (XXXX) XXX XXXXXXXXXXXXX. (Motif Bio, XXXX) Next, the company has to brand its products properly for widespread XXXXXX XXXXXXXXXX, XXXXXXX means XXXX as XXXXXXXX/XXXXXX XXXXX marketing, tradeshow exhibitions XXX XXXXXX lectures. Finally, XXX XXXXXXX is XXXXXXXXXXX for XXXXXX XXXXXXXXXXX, in order to ensure that a XXXXXXX and capable team XXXXXXXXXX XXXXXXXX researchers, XXXXXXXXXXX, bio-engineers and doctors is able to conduct rigorous and effective research XX XXXXXXX novel XXXX-multi-drug-XXXXXXXXX bacteria drugs, as XXXX as publish research in XXXXXXXX journals such XX XXXXXX XX ensure that XXXXX Bio stays XX the forefront of innovative XXXXXXXXXXXXXXXXX XXXXXXXX.
XXX XXXXXXXXXXXX plays an important XXXX in the U.S. XXXXXXXXXX XXXXXX as a XXXXXXXXXXXXXXXXX XXXXXXX, XXX works XXXX XXXXXXXXX, healthcare providers and the XXXXXXXXXX . XXXXXXX XXXX XXXXX XXXX XXXX 10 million XXXXXXXXXXX XXXXXXXX are anticipated to XXX from XXXX-resistant bacterial infections XX XXXX, XXXX XX,XXX XXXXXX per year in XXX X.S. at present. (XXXXXXXXXX XXX Piddock, 2018) XX response XX XXXX XXXXXXXX trend, XXXXX Bio has XXXXXXXXX XXXXX anti-MRSA antibiotic XXXXXXXXX. XXXX XXXXXX a key XXXX in XXX X.S. XXXXXXXXXX system, by (a) XXXXXXXX the XXXX of healthcare providers and XXXXXXXXX, (b) collaborating XXXX hospitals to XXXXXX XXXX XXX XXXXXXXXX drug XXXXXX, and (c) XXXXXXX within XXX government’s support XXXXXXX XXX XXXXXXXXXX XXXXXXXXXX XX XXXXXX XXXXXXXXXX XXXXXXXXXX. XXXXXXXX, XXXXX XXX enables the work XX healthcare providers and XXXXXXXXX XX providing XXXXX XXXXXXXXXX XXXXXXXXX XX combat XXX scourge XX XXXXX-XXXX XXXXXXXXX XXXXXXXX. (XXXXXX, XXXX) This XXX the XXXXXX of enabling XXXX to XXXX lives, XXXXXXX XXXX XXXXXXXXX XXXXXXXXX, carry out high XXXXXXXXX XXXX procedures XXXX XX surgeries, XXX save costs XX multi-XXXX resistant antibacterial infections. Secondly, XXXXX Bio XXXXX with hospitals to XXXXXXX XXXX and efficient XXXX XXXXXX XX consenting XXXXXXXX. XXXXXXX, the XXXXXXXXXX XXXXXXXX XXXXX Bio’s XXXX through accomodative XXXXXXXXXX XXXXXXXXXX and financial subsidies.
XX XXXXXXXXXX, XXXXX XXX, like XXXXX innovative pharmaceutical companies, plays an XXXXXXXXX role in XXX X.S. XXXXXXXXXX XXXXXX XXXXXXX XXX work on XXXXXXXXXXX and producing novel antibiotic XXXXXXXXX to multi-drug XXXXXXXXX XXXXXXXX.
XXXXXXXXXX
XXXXXXX, N., XXXXXXXXXX, L., & XXXXXXX, X. J. (XXXX). XXXXXXXXX XXX development of new antibacterial XXXXX: learning XXXX experience?.XXXXXXX XX Antimicrobial XXXXXXXXXXXX,XX(X), XXXX-1459.
Motif XXX. (2015). Phase 3 study to evaluate XXXXXX and efficacy of XXXXXXXX XXXXXX vancomycin XXX ABSSSI: XXXXXX-2 (XXXXXX-2).ClinicalTrials. gov XXXXXXXXXX NCT02600611. XXXXX://clinicaltrials. XXX/XXX/show/XXXXXXXXXXX.
XXXXX XXX. (XXXX, January XX). XXXXX Motif XXX. Retrieved 2019, XXXXX XX XXXX XXXXX://www.motifbio.com/about/
Schneider, X., XXXXXX, S., & XXXXX, X. (XXXX). Iclaprim, a novel diaminopyrimidine with potent activity on XXXXXXXXXXXX sensitive and resistant bacteria.XXXXXXXXXX & XXXXXXXXX chemistry XXXXXXX,13(XX), 4217-4221.
XXXXXX, G. X., & Sutherland, X. X. (XXXX). New XXXXXXXXXX for combating XXXXXXXXX-XXXXXXXXX XXXXXXXX.Trends in XXXXXXXXX XXXXXXXX,13(6), 260-267.
">